Quick Overview
Ipamorelin and CJC-1295 are almost always mentioned together, and for good reason — they're not competing options for the same job. They stimulate growth hormone release through two entirely separate receptor pathways, which is exactly why research protocols frequently combine them rather than picking one.
Ipamorelin
A pentapeptide ghrelin-receptor (GHS-R1a) agonist developed by Novo Nordisk. Known for GH release without significantly disturbing cortisol, ACTH or other pituitary hormones.
CJC-1295 (No DAC)
A modified GHRH analog, engineered for a more sustained GHRH signal than native GHRH in preclinical models.
Mechanism Compared
Ipamorelin binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, triggering pulsatile GH release. Its founding characterization — Raun et al., 1998, European Journal of Endocrinology — found it did this without significantly raising ACTH or cortisol the way older secretagogues like GHRP-6 did, and without moving FSH, LH, prolactin or TSH. CJC-1295 (No DAC) works upstream on a different receptor entirely: it binds GHRH receptors in the anterior pituitary, stimulating synthesis and release of growth hormone via the body's natural GHRH pathway, with a modified amino-acid sequence that resists enzymatic degradation for a more sustained signal than native GHRH.
Why They're Usually Stacked, Not Compared
Because GHRH analogs and ghrelin-receptor agonists act on distinct receptors upstream of GH release, combining CJC-1295 and Ipamorelin is a common research design intended to examine potential synergistic effects on GH pulse amplitude — hitting the same downstream outcome (GH release) from two different upstream triggers. This is the actual research rationale behind the pairing, not just a marketing convention. Controlled human trials of the specific combination remain limited, however — most of the mechanistic support for the pairing comes from understanding each receptor pathway individually, not from a dedicated combination trial.
Dosing Guide
What the research shows
Neither compound has an FDA-approved human dosage. Ipamorelin's founding data comes from in-vivo animal pharmacology (Raun et al. 1998); CJC-1295 doses used in preclinical and small clinical research studies vary by study design and are not established as a standardized human protocol.
Compound X does not provide dosing recommendations. Both peptides are sold for laboratory research use only and are not intended for human consumption.
Side Effects Compared
Neither has completed large-scale controlled human trials. Ipamorelin's reported concerns include injection-site reactions and transient flushing, with theoretical long-term GH-axis concerns that haven't been fully characterized in humans. CJC-1295's reported concerns are similar — injection-site reactions and, due to its GH-axis activity, theoretical concerns about insulin sensitivity not fully characterized in long-term human data. Their safety profiles are comparably under-documented.
The Verdict
This is a "both," not an "either"
Ipamorelin and CJC-1295 aren't really rivals — they're complementary tools acting on separate receptors. The research rationale for pairing them is real and mechanistically sound; the gap is that a dedicated human combination trial doesn't exist to confirm the theorized synergy directly.
FAQ
Do Ipamorelin and CJC-1295 do the same thing?
No. Ipamorelin acts on the ghrelin receptor (GHS-R1a); CJC-1295 acts on the GHRH receptor. Both ultimately promote GH release, but through separate upstream pathways.
Is there human trial data on combining them?
Not a dedicated controlled trial. The rationale for combining them is built on understanding each receptor pathway separately, not on a published combination RCT.
Which one is more "selective"?
Ipamorelin is specifically noted for not disturbing cortisol, ACTH or other pituitary hormones in its founding 1998 study — that's the basis for its "selective" reputation. CJC-1295 acts through a different, receptor-specific pathway (GHRH) that doesn't carry the same cortisol-spillover concern in the first place.
References
Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology. 1998;139(5):552-561. CJC-1295 GHRH-analog pharmacology as characterized in preclinical receptor-binding literature.
